Finn's Take· TL;DRFor people living with stiff person syndrome, daily life can feel like a slow disappearance. The rare autoimmune neurologic disease causes progressive muscle stiffness and painful spasms that can make walking, driving, working, and socializing increasingly difficult. There has been no cure — until now, researchers may be inching closer to one. A multicenter clinical trial evaluating CAR-T cell therapy for stiff person syndrome has produced promising early results, with the study published on November 9, 2026 in *JAMA Neurology*.
Singer Celine Dion announced she had been diagnosed with stiff person syndrome in 2022. Her openness about the condition helped pull it out of obscurity. Two years after sharing her diagnosis, the Céline Dion Foundation pledged $2 million into funding, which has since gone on to support critical research. That investment now appears to be bearing fruit.
CAR-T cell therapy reengineers a patient's own immune cells to target other cells contributing to disease. Study participants received a single treatment designed to reset the immune system and reduce symptoms that can profoundly limit daily life. The idea is elegant in its logic: rather than managing symptoms indefinitely with medication, the therapy attempts to correct the underlying immune malfunction at its source.
The trial, presented at the 2026 American Academy of Neurology Annual Meeting in April, involved 26 adults with SPS and found that around four months after treatment, the walking speed of all patients had improved, while eight of 12 who had previously relied on a walking aid no longer needed it. Those are not small numbers for a disease that has long offered patients very little. Participants in the trial who previously required assistance with daily tasks regained mobility and returned to work.
The human story behind the data is equally striking. Doctors at the Mayo Clinic said patients who once needed help with basic daily tasks and struggled to walk have regained everyday life. One patient described walking on a treadmill again after the treatment — a milestone that would seem ordinary to most people but represented an enormous reclamation of independence.
Dr. Sean Pittock, chairman of the department of neurology at Mayo Clinic, said that CAR-T therapy has already transformed the treatment of some cancers, and that the results "offer tremendous hope, not only for people living with this disease but potentially for patients with other immune-mediated neurologic conditions where effective treatment options remain limited." That broader implication is significant — SPS may be rare, but the immune system mechanisms involved are shared with other serious conditions.
Researchers are careful not to get ahead of the science. "What was most striking was the degree of improvement we saw in some patients. These early results are very encouraging, and the key question now is whether those improvements will be sustained over time," said Dr. Anastasia Zekeridou, a neurologist and researcher at Mayo Clinic in Rochester. Durability is the critical unknown — whether a single treatment can deliver lasting relief or whether patients will eventually relapse remains to be seen.
Mayo Clinic researchers say larger trials could follow, but it is unclear if the gains will last. Still, the trajectory is undeniably encouraging. The trial evaluated miv-cel, a treatment aimed at becoming the first approved therapy for the condition. For the thousands of people worldwide living with a disease that was barely on the medical radar before Celine Dion put a famous face to it, the publication of these results marks a turning point — not a finish line, but perhaps the clearest sign yet that one is within reach.